Delivery Order SPE2DR25D3016-SPE2DR26FG2EH
- Not listed
- The Defense Logistics Agency awarded a $28,634.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on August 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999, which runs through December 2026. The performance location is the company's corporate office in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order valued at $13,647.72 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on May 27, 2025, with a completion date of May 28, 2025. This competitive award, placed under a firm fixed-price contract, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $28,427.31 to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 ml pen injections on December 12, 2025, with a completion date of December 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,525.20 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 ml pen injections on August 27, 2025, with an ultimate completion date of August 28, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through December 2026. The product will be...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,458.10 on December 5, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injections. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's distribution facility in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order valued at $16,711.96 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pens on December 9, 2025, with an ultimate completion date of December 10, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a $40,364.43 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on September 22, 2025, with an ultimate completion date of September 23, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive global pharmaceutical support vehicle running through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $8,768.60 to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pens on October 28, 2025, with completion targeted for October 29, 2025. This competitive, non-set-aside award utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. The product will be delivered...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Zepbound 10 mg/0.5 mL pens with a ceiling value of $7,462.47. This is a firm fixed-price delivery order with an ultimate completion date of December 11, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $11,161.15 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on August 5, 2025, with completion scheduled for August 6, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively through an open procurement process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- SPE2DR25D3016Indefinite Delivery Contract
- SPE2DR25D3016-SPE2DR26FG2EHDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $25,155.58 firm fixed-price delivery order for Zepbound 2.5 mg/0.5 mL pens on December 12, 2025, with an ultimate completion date of December 15, 2025. This contract was competitively awarded with no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for chronic weight management in adults with obesity or overweight conditions. This delivery order reflects DLA's ongoing procurement of specialty pharmaceutical products to support military healthcare systems and other federal medical supply chain requirements. AmerisourceBergen, as a major pharmaceutical distributor, maintains a comprehensive portfolio of brand-name and generic medications through its prime contract with DLA, enabling it to fulfill varied federal medical procurement needs through open competition across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.2k | 12/11/25 |